Reports

US Multiple Sclerosis Therapeutics Market Analysis

The US multiple sclerosis therapeutics market is projected to grow from $18.2 Bn in 2022 to $27.7 Bn by 2030, registering a CAGR of 5.38% during the forecast period of 2022?30. The two reasons propelling market expansion are the prevalence of multiple sclerosis (MS) is rising, and funding for MS research is rising as well. Major global players in this market are Abbott (U.S.), Bristol-Myers Squibb Company (U.S.), Teva Pharmaceutical Industries Ltd (Israel), Takeda Pharmaceutical Company Limited (Japan), Jazz Pharmaceuticals, Inc. (U.K.), Novartis AG (Switzerland), Biora Therapeutics, Inc. (U.S.), Bausch Health Companies Inc. (Canada), Pfizer Inc. (U.S.), Novartis AG (Switzerland), and Mylan N.V. (U.S.)